Abstract
We analyzed the disease-specific outcomes of adult patients with advanced myelodysplastic syndrome (MDS) treated with cord blood transplantation (CBT) after myeloablative conditioning. Between August 1998 and June 2009, 33 adult patients with advanced MDS were treated with unrelated CBT. The diagnoses at transplantation included refractory anemia with excess blasts (n=7) and MDS-related secondary AML (sAML) (n=26). All patients received four fractionated 12 Gy TBI and chemotherapy as myeloablative conditioning. The median age was 42 years, the median weight was 55 kg and the median number of cryopreserved nucleated cells was 2.51 × 107 cells per kg. The cumulative incidence of neutrophil recovery at day 50 was 91%. Neutrophil recovery was significantly faster in sAML patients (P=0.04). The cumulative incidence of plt recovery at day 200 was 88%. Plt recovery was significantly faster in CMV seronegative patients (P<0.001). The cumulative incidence of grade II–IV acute GVHD (aGVHD) and extensive-type chronic GVHD was 67 and 34%, respectively. Degree of HLA mismatch had a significant impact on the incidence of grade II–IV aGVHD (P=0.021). TRM and relapse at 5-years was 14 and 16%, respectively. The probability of EFS at 5 years was 70%. No factor was associated with TRM, relapse and EFS. These results suggest that adult advanced MDS patients without suitable related or unrelated BM donors should be considered as candidates for CBT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
de Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myelogenous leukemia following MDS of more than 6 months duration. A pilot study by the leukemia cooperative group of the european organisation for research and treatment in cancer (EORTC-LCG). Leukemia 1995; 9: 1805–1810.
Anderson JE, Anasetti C, Appelbaum FR, Schoch G, Gooley TA, Hansen JA et al. Unrelated donor transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukemia. Br J Haematol 1996; 93: 59–67.
Arnold R, de Witte T, van Biezen A, Hermans J, Jacobsen N, Runde V et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. Bone Marrow Transplant 1998; 21: 1213–1216.
de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the chronic leukaemia working party of the european group for blood and marrow transplantation (EBMT). Br J Haematol 2000; 110: 620–630.
de Witte T, Pikkemaat F, Hermans J, van Biezen A, Mackinnan S, Cornelissen J et al. Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation. Leukemia 2001; 15: 1878–1884.
Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002; 100: 1201–1207.
Laughlin MJ, Barker J, Bambach B, Omeb NK, Rizzieri DA, Wagner JE et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001; 344: 1815–1822.
Gluckman E . Current status of umbilical cord blood hematopoietic stem cell transplantation. Exp Hematol 2000; 28: 1197–1205.
Sanz GF, Saavedra S, Planelles D, Senent L, Cervera J, Barragan E et al. Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood 2001; 98: 2332–2338.
Long GD, Laughlin M, Madan B, Kurtzberg J, Gasparetto C, Morris A et al. Unrelated umbilical cord blood transplantation in adult patients. Biol Blood Marrow Transplant 2003; 9: 772–780.
Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265–2275.
Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276–2285.
Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematological malignancies. Blood 2004; 104: 3813–3820.
Arcese W, Rocha V, Labopin M, Sanz G, Iori AP, de Lima M et al. Unrelated cord blood transplants in adults with hematologic malignancies. Haematologica 2006; 91: 223–230.
Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem cell transplantation from related donors in adult patients with hematological malignancies after myeloablative conditioning regimen. Blood 2007; 109: 1322–1330.
Ooi J, Iseki T, Takahashi S, Tomonari A, Ishii K, Takasugi K et al. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 2003; 101: 4711–4713.
Ooi J . The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome. Leuk Lymphoma 2006; 47: 599–602.
Armand P, Deeg HJ, Kim HT, Lee H, Armistead P, de Lima M et al. Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. Bone Marrow Transplant (e-pub ahead of print 28 September 2009; doi:10.1038/bmt.2009.253).
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.
Ooi J, Takahashi S, Tomonari A, Tsukada N, Konuma T, Kato S et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia. Biol Blood Marrow Transplant 2008; 14: 1341–1347.
Ooi J, Takahashi S, Tomonari A, Tsukada N, Konuma T, Kato S et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with ALL. Bone Marrow Transplant 2009; 43: 455–459.
Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 2009; 113: 1631–1638.
Sanz J, Sanz MA, Saavedra S, Lorenzo I, Montesinos P, Senent L et al. Cord blood transplantation from unrelated donors in adults with high risk acute myeloid leukemia. Biol Blood Marrow Transplant 2010; 16: 86–94.
Tomonari A, Takahashi S, Ooi J, Tsukada N, Konuma T, Kato S et al. Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan. Eur J Haematol 2008; 80: 251–257.
Acknowledgements
We thank the physicians and nurses who cared for patients in this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Sato, A., Ooi, J., Takahashi, S. et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes. Bone Marrow Transplant 46, 257–261 (2011). https://doi.org/10.1038/bmt.2010.91
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.91
Keywords
This article is cited by
-
Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies
Annals of Hematology (2022)
-
Umbilical cord blood donation: public or private?
Bone Marrow Transplantation (2015)
-
Prophylactic and therapeutic treatment of graft-versus-host disease in Japan
International Journal of Hematology (2015)
-
Allogeneic hematopoietic cell transplantation from alternative sources for adult Philadelphia chromosome-negative ALL: what should we choose when no HLA-matched related donor is available?
Bone Marrow Transplantation (2013)
-
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: Current Status
Archivum Immunologiae et Therapiae Experimentalis (2012)